Literature DB >> 33025093

Optimal 68Ga-PSMA and 18F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer.

Cédric Draulans1,2, Robin De Roover3,4, Uulke A van der Heide5, Linda Kerkmeijer6,7, Robert J Smeenk6, Floris Pos5, Wouter V Vogel8, James Nagarajah9, Marcel Janssen9, Sofie Isebaert3,4, Frederik Maes10,11, Cindy Mai12, Raymond Oyen12, Steven Joniau13,14, Martina Kunze-Busch6, Karolien Goffin15, Karin Haustermans16,17.   

Abstract

PURPOSE: This study proposes optimal tracer-specific threshold-based window levels for PSMA PET-based intraprostatic gross tumour volume (GTV) contouring to reduce interobserver delineation variability.
METHODS: Nine 68Ga-PSMA-11 and nine 18F-PSMA-1007 PET scans including GTV delineations of four expert teams (GTVmanual) and a majority-voted GTV (GTVmajority) were assessed with respect to a registered histopathological GTV (GTVhisto) as the gold standard reference. The standard uptake values (SUVs) per voxel were converted to a percentage (SUV%) relative to the SUVmax. The statistically optimised SUV% threshold (SOST) was defined as those that maximises accuracy for threshold-based contouring. A leave-one-out cross-validation receiver operating characteristic (ROC) curve analysis was performed to determine the SOST for each tracer. The SOST analysis was performed twice, first using the GTVhisto contour as training structure (GTVSOST-H) and second using the GTVmajority contour as training structure (GTVSOST-MA) to correct for any limited misregistration. The accuracy of both GTVSOST-H and GTVSOST-MA was calculated relative to GTVhisto in the 'leave-one-out' patient of each fold and compared with the accuracy of GTVmanual.
RESULTS: ROC curve analysis for 68Ga-PSMA-11 PET revealed a median threshold of 25 SUV% (range, 22-27 SUV%) and 41 SUV% (40-43 SUV%) for GTVSOST-H and GTVSOST-MA, respectively. For 18F-PSMA-1007 PET, a median threshold of 42 SUV% (39-45 SUV%) for GTVSOST-H and 44 SUV% (42-45 SUV%) for GTVSOST-MA was found. A significant pairwise difference was observed when comparing the accuracy of the GTVSOST-H contours with the median accuracy of the GTVmanual contours (median, - 2.5%; IQR, - 26.5-0.2%; p = 0.020), whereas no significant pairwise difference was found for the GTVSOST-MA contours (median, - 0.3%; IQR, - 4.4-0.6%; p = 0.199).
CONCLUSIONS: Threshold-based contouring using GTVmajority-trained SOSTs achieves an accuracy comparable with manual contours in delineating GTVhisto. The median SOSTs of 41 SUV% for 68Ga-PSMA-11 PET and 44 SUV% for 18F-PSMA-1007 PET form a base for tracer-specific window levelling. TRIAL REGISTRATION: Clinicaltrials.gov ; NCT03327675; 31-10-2017.

Entities:  

Keywords:  Delineation; Focal boost; PSMA PET; Prostatic neoplasms; Radiotherapy

Year:  2020        PMID: 33025093     DOI: 10.1007/s00259-020-05059-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  16 in total

1.  Prostate tumor delineation using multiparametric magnetic resonance imaging: Inter-observer variability and pathology validation.

Authors:  Peter Steenbergen; Karin Haustermans; Evelyne Lerut; Raymond Oyen; Liesbeth De Wever; Laura Van den Bergh; Linda G W Kerkmeijer; Frank A Pameijer; Wouter B Veldhuis; Jochem R N van der Voort van Zyp; Floris J Pos; Stijn W Heijmink; Robin Kalisvaart; Hendrik J Teertstra; Cuong V Dinh; Ghazaleh Ghobadi; Uulke A van der Heide
Journal:  Radiother Oncol       Date:  2015-04-29       Impact factor: 6.280

2.  18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics.

Authors:  Kambiz Rahbar; Ali Afshar-Oromieh; Martin Bögemann; Stefan Wagner; Michael Schäfers; Lars Stegger; Matthias Weckesser
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-14       Impact factor: 9.236

3.  [68Ga-]PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard - Implications for focal radiotherapy planning in primary prostate cancer.

Authors:  Alisa S Bettermann; Constantinos Zamboglou; Selina Kiefer; Cordula A Jilg; Simon Spohn; Jasmin Kranz-Rudolph; Thomas F Fassbender; Peter Bronsert; Nils H Nicolay; Christian Gratzke; Michael Bock; Juri Ruf; Matthias Benndorf; Anca L Grosu
Journal:  Radiother Oncol       Date:  2019-08-17       Impact factor: 6.280

4.  Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference.

Authors:  Constantinos Zamboglou; Thomas F Fassbender; Lina Steffan; Florian Schiller; Tobias Fechter; Montserrat Carles; Selina Kiefer; Hans C Rischke; Kathrin Reichel; Nina-Sophie Schmidt-Hegemann; Harun Ilhan; Alin F Chirindel; Guillaume Nicolas; Christoph Henkenberens; Thorsten Derlin; Peter Bronsert; Panayiotis Mavroidis; Ronald C Chen; Philipp T Meyer; Juri Ruf; Anca L Grosu
Journal:  Radiother Oncol       Date:  2019-08-17       Impact factor: 6.280

5.  Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer.

Authors:  Patrick A Kupelian; Jay Ciezki; Chandana A Reddy; Eric A Klein; Arul Mahadevan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-08       Impact factor: 7.038

6.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

7.  Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial.

Authors:  Irene M Lips; Uulke A van der Heide; Karin Haustermans; Emile N J T van Lin; Floris Pos; Stefan P G Franken; Alexis N T J Kotte; Carla H van Gils; Marco van Vulpen
Journal:  Trials       Date:  2011-12-05       Impact factor: 2.279

8.  Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy.

Authors:  Isabel Rauscher; Markus Krönke; Michael König; Andrei Gafita; Tobias Maurer; Thomas Horn; Kilian Schiller; Wolfgang Weber; Matthias Eiber
Journal:  J Nucl Med       Date:  2019-06-28       Impact factor: 11.082

9.  F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.

Authors:  Frederik L Giesel; B Hadaschik; J Cardinale; J Radtke; M Vinsensia; W Lehnert; C Kesch; Y Tolstov; S Singer; N Grabe; S Duensing; M Schäfer; O C Neels; W Mier; U Haberkorn; K Kopka; C Kratochwil
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-26       Impact factor: 9.236

10.  Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.

Authors:  David P Dearnaley; Gordana Jovic; Isabel Syndikus; Vincent Khoo; Richard A Cowan; John D Graham; Edwin G Aird; David Bottomley; Robert A Huddart; Chakiath C Jose; John H L Matthews; Jeremy L Millar; Claire Murphy; J Martin Russell; Christopher D Scrase; Mahesh K B Parmar; Matthew R Sydes
Journal:  Lancet Oncol       Date:  2014-02-26       Impact factor: 41.316

View more
  11 in total

1.  Machine learning-based radiomics for multiple primary prostate cancer biological characteristics prediction with 18F-PSMA-1007 PET: comparison among different volume segmentation thresholds.

Authors:  Kun Tang; Yunjun Yang; Fei Yao; Shuying Bian; Dongqin Zhu; Yaping Yuan; Kehua Pan; Zhifang Pan; Xianghao Feng
Journal:  Radiol Med       Date:  2022-08-26       Impact factor: 6.313

2.  Correlation Between Quantitative PSMA PET Parameters and Clinical Risk Factors in Non-Metastatic Primary Prostate Cancer Patients.

Authors:  Sebastian Zschaeck; Stephanie Bela Andela; Holger Amthauer; Christian Furth; Julian M Rogasch; Marcus Beck; Frank Hofheinz; Kai Huang
Journal:  Front Oncol       Date:  2022-04-22       Impact factor: 5.738

3.  Feasibility of biology-guided radiotherapy using PSMA-PET to boost to dominant intraprostatic tumour.

Authors:  Mathieu Gaudreault; David Chang; Nicholas Hardcastle; Price Jackson; Tomas Kron; Michael S Hofman; Shankar Siva
Journal:  Clin Transl Radiat Oncol       Date:  2022-05-17

4.  Prostate cancer GTV delineation with biparametric MRI and 68Ga-PSMA-PET: comparison of expert contours and semi-automated methods.

Authors:  Nathan Hearn; John Blazak; Philip Vivian; Dinesh Vignarajah; Katelyn Cahill; Daisy Atwell; Jim Lagopoulos; Myo Min
Journal:  Br J Radiol       Date:  2021-01-28       Impact factor: 3.039

5.  Comparison of Manual and Semi-Automatic [18F]PSMA-1007 PET Based Contouring Techniques for Intraprostatic Tumor Delineation in Patients With Primary Prostate Cancer and Validation With Histopathology as Standard of Reference.

Authors:  Simon K B Spohn; Maria Kramer; Selina Kiefer; Peter Bronsert; August Sigle; Wolfgang Schultze-Seemann; Cordula A Jilg; Tanja Sprave; Lara Ceci; Thomas F Fassbender; Nils H Nicolay; Juri Ruf; Anca L Grosu; Constantinos Zamboglou
Journal:  Front Oncol       Date:  2020-12-07       Impact factor: 6.244

6.  Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients.

Authors:  S K B Spohn; S Adebahr; M Huber; C Jenkner; R Wiehle; B Nagavci; C Schmucker; E G Carl; R C Chen; W A Weber; M Mix; A Rühle; T Sprave; N H Nicolay; C Gratzke; M Benndorf; T Wiegel; J Weis; D Baltas; A L Grosu; C Zamboglou
Journal:  BMC Cancer       Date:  2022-03-28       Impact factor: 4.430

7.  Gross tumor volume delineation in primary prostate cancer on 18F-PSMA-1007 PET/MRI and 68Ga-PSMA-11 PET/MRI.

Authors:  Yan-Nan Zhang; Zhen-Guo Lu; Shuai-Dong Wang; Xin Lu; Lei-Lei Zhu; Xu Yang; Li-Ping Fu; Jun Zhao; Hai-Feng Wang; Zuo-Lin Xiang
Journal:  Cancer Imaging       Date:  2022-07-22       Impact factor: 5.605

8.  Feasibility of Different Tumor Delineation Approaches for 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients.

Authors:  Lena M Mittlmeier; Matthias Brendel; Leonie Beyer; Nathalie L Albert; Andrei Todica; Mathias J Zacherl; Vera Wenter; Annika Herlemann; Alexander Kretschmer; Stephan T Ledderose; Nina-Sophie Schmidt-Hegemann; Wolfgang G Kunz; Jens Ricke; Peter Bartenstein; Harun Ilhan; Marcus Unterrainer
Journal:  Front Oncol       Date:  2021-05-21       Impact factor: 6.244

9.  Influence of Urethra Sparing on Tumor Control Probability and Normal Tissue Complication Probability in Focal Dose Escalated Hypofractionated Radiotherapy: A Planning Study Based on Histopathology Reference.

Authors:  Simon K B Spohn; Ilias Sachpazidis; Rolf Wiehle; Benedikt Thomann; August Sigle; Peter Bronsert; Juri Ruf; Matthias Benndorf; Nils H Nicolay; Tanja Sprave; Anca L Grosu; Dimos Baltas; Constantinos Zamboglou
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

10.  68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data.

Authors:  Paola Mapelli; Samuele Ghezzo; Ana Maria Samanes Gajate; Erik Preza; Anna Palmisano; Vito Cucchiara; Giorgio Brembilla; Carolina Bezzi; Riccardo Rigamonti; Patrizia Magnani; Elisa Toninelli; Valentino Bettinardi; Nazareno Suardi; Luigi Gianolli; Paola Scifo; Alberto Briganti; Francesco De Cobelli; Antonio Esposito; Maria Picchio
Journal:  Cancers (Basel)       Date:  2022-01-11       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.